anti-SARS-CoV-2 cocktail antibodies WEHI, Myrio Therapeutics, Burnet Institute, Kirby Institute (Doherty Institute)

N/A

Report date: 2025/01/26 19:31:47

Base Information

Drug Nameanti-SARS-CoV-2 cocktail antibodies WEHI, Myrio Therapeutics, Burnet Institute, Kirby Institute (Doherty Institute)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesWalter And Eliza Hall Institute Of Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesKirby InstituteThe Macfarlane Burnet Institute For Medical Research And Public Health LtdCopyright The Peter Doherty Institute For Infection And Immunity +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A